Nirmatrelvir Resistance—de Novo E166V/L50V Mutations in an Immunocompromised Patient Treated With Prolonged Nirmatrelvir/Ritonavir Monotherapy Leading to Clinical and Virological Treatment Failure—a Case Report

Neta S. Zuckerman, Efrat Bucris, Danielle Keidar-Friedman, Muriel Amsalem, Tal Brosh-Nissimov

Research output: Contribution to journalArticlepeer-review

15 Scopus citations

Abstract

Resistance of SARS-CoV-2 to antivirals was shown to develop in immunocompromised individuals receiving remdesivir. We describe an immunocompromised patient who was treated with repeated and prolonged courses of nirmatrelvir and developed de-novo E166V/L50F mutations in the Mpro region. These mutations were associated with clinical and virological treatment failure.

Original languageEnglish
Pages (from-to)352-355
Number of pages4
JournalClinical Infectious Diseases
Volume78
Issue number2
DOIs
StatePublished - 17 Feb 2024
Externally publishedYes

Bibliographical note

Publisher Copyright:
© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved.

Keywords

  • E166V/L50F
  • M
  • immunocompromised
  • nirmatrelvir
  • resistance

Fingerprint

Dive into the research topics of 'Nirmatrelvir Resistance—de Novo E166V/L50V Mutations in an Immunocompromised Patient Treated With Prolonged Nirmatrelvir/Ritonavir Monotherapy Leading to Clinical and Virological Treatment Failure—a Case Report'. Together they form a unique fingerprint.

Cite this